Uralbiopharm

Performance indicators

2023: Revenue growth by a third to RUB 1.71 billion

At the end of 2023, Uralbiopharm increased revenue by a third to 1.71 billion rubles from 1.28 billion rubles in 2022. The net profit of the Yekaterinburg pharmaceutical enterprise during this time increased 1.7 times - from 105.8 million to 176.1 million rubles. Such data in accordance with Russian accounting standards (RAS) were disclosed in early April 2024.

According to the Interfax] agency, citing materials from Uralbiopharm, in 2023 the cost of sales of the plant amounted to 963.1 million rubles, an increase of 25% compared to a year ago. Gross profit increased by 47.4% (from 509.2 million to 750.5 million rubles), profit from sales - 1.9 times (from 235.4 million to 441.2 million rubles), profit before tax - 1.6 times (from 137.6 million to 221.3 million rubles).

𝓲

Unsplash

Payables of Uralbiofarm as of December 31, 2023 amounted to 170.3 million rubles against 216.5 million rubles a year earlier. The company's receivables increased from 455.8 million rubles to 504.1 million rubles.

As of the end of 2023, Uralbiopharm produces drugs of various pharmacotherapeutic groups, including vital and some brands intended for the symptomatic treatment of viral and colds.^[1]

History

2024: New CEO Alexander Serebrennikov appointed

At the end of July 2024, it became known that the deputy of the legislative assembly of the Sverdlovsk region, Alexander Serebrennikov (ex-owner of the Rainbow pharmacy chain), was appointed head of the Uralbiopharm enterprise. The new manager reported identifying problems with the company. Read more here

2023: The court seized Uralbiopharm shares worth 3 billion rubles in favor of the state

In mid-August 2023, the Leninsky District Court of Yekaterinburg satisfied the claim of the Deputy Prosecutor General of the Russian Federation Igor Tkachev and seized from the former State Duma deputy Malika Gaysin the shares of the Uralbiopharm company worth 3 billion rubles in favor of the state. Read more here.

Notes